Cingulate Inc. 8-K

What Happened
Cingulate Inc. announced on Jan. 12, 2026 (filed via Form 8-K on Jan. 15, 2026) that it increased the maximum aggregate offering price of shares issuable under its At-The-Market (ATM) Sales Agreement with H.C. Wainwright & Co., LLC from $23,536,658 to $31,936,658. The company also filed a prospectus supplement (the Current Prospectus Supplement) covering an aggregate of $8,840,000 of Common Stock. The Sales Agreement was originally dated Jan. 3, 2023.

Key Details

• Date of action: January 12, 2026 (8-K filed January 15, 2026).
• New ATM capacity: increased to $31,936,658 (previously $23,536,658).
• Prospectus supplement filed covering $8,840,000 of Common Stock.
• Prior sales under the Sales Agreement totaled $15,145,503.74.
• Legal opinion regarding the $8,840,000 of shares was filed as Exhibit 5.1 to the 8-K.

Why It Matters
This change expands Cingulate’s ability to raise capital quickly by selling shares into the market through its ATM program. For investors, that means the company has greater flexibility to fund operations or development programs without a traditional registered offering—but it also increases the potential for future share dilution if the company sells additional shares. The filing of the prospectus supplement and legal opinion completes the regulatory steps needed to offer the additional shares under the Sales Agreement.